- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01504984
Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers
An Open-label, Randomized, Single Dose, Crossover Phase I Clinical Trial to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab., 4T (400mg) in Healthy Male Volunteers
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Healthy volunteers are administrated single-dose over the period I and II (crossover) of SYO-1126 and Glivec Film Coated tab 4T (400mg) as of imatinib 400mg.
Every time before and after each medication, pharmacokinetic (PK) parameters and safety of SYO-1126 and Glivec Film Coated tab 4T (400mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Korea, Republikken
- Severance Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Between 20aged and 45aged in healthy males
- Over 55kg and BMI: 18.5~25 kg/m2
- Agreement with written informed consent
Exclusion Criteria:
- Subject with symptoms of acute disease at the time of screening
- Clinically significant cardiovascular system, pulmonary system, renal system, endocrine system, blood system, gastrointestinal system, nervous system, mental disease or malignant tumor
- Subject with known for gastrointestinal disease or surgical history which affect on absorption of drug
- An impossible one who participates in clinical trial by result of screening tests
- Inadequate result of laboratory test AST/ALT > 1.5 x UNL Total bilirubin > 1.5 X UNL
- Clinically significant allergic disease(Except for mild allergic rhinitis seems to be not need for medication)
- Subject with known for hypersensitivity reaction to imatinib analog
- Subject with known for history which drug abuse or show positive for it in screening tests
- Previously participate in other trial within 60 days
- Previously make whole blood donation within 60 days or component blood donation within 30 days
- Previously have blood transfusion within 30 days
- Not able to taking the institutional standard meal
- Subject who have had abnormal eating which affect on the ADME of drug
- Not able to taking the grapefruit-containing foods
- Taking ETC(ethical the counter)medicine including oriental medicine within 14 days or taking OTC(over the counter)medicine or vitamin preparations within 7 days
- Continued to be taking caffein(caffein>5cup/day), drinking (alcohol>30g/day) and severe heavy smoker(cigarette>1/2pack/day)
- An impossible one who participates in clinical trial by investigator's decision including for reason laboratory test result
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: SYO-1126
Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
|
Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
Andre navne:
|
Aktiv komparator: Glivec film coated tab 4T(400mg)
100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
|
Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Pharmacokinetics of the AUCt SYO-1126 anf Glivec Film coated tab 4T(400mg)
Tidsramme: 0-72hr
|
0-72hr
|
Pharmacokinetics of the Cmax SYO-1126 anf Glivec Film coated tab 4T(400mg)
Tidsramme: 0-72hr
|
0-72hr
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Pharmacokinetics of the AUCinf SYO-1126 and Glivec Film Coated 4T(400mg)
Tidsramme: 0-72hr
|
0-72hr
|
Evaluation of the safety of SYO-1126 and Glivec Film Coated 4T(400mg) from vital signs, physical exam, ECG, laboratory test, adverse events and so on.
Tidsramme: 20~24 days
|
20~24 days
|
Pharmacokinetics of the Tmax of SYO-1126 and Glivec Film Coated 4T(400mg)
Tidsramme: 0-72hr
|
0-72hr
|
Pharmacokinetics of the T1/2 of SYO-1126 and Glivec Film Coated 4T(400mg)
Tidsramme: 0-72hr
|
0-72hr
|
Pharmacokinetics of the CL/F of SYO-1126 and Glivec Film Coated 4T(400mg)
Tidsramme: 0-72hr
|
0-72hr
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Min Su Park, Doctor, Severance Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SYO1126
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med SYO-1126
-
InvicroAfsluttetParkinsons sygdom | Alzheimers sygdom | Sunde frivilligeForenede Stater
-
Samyang Biopharmaceuticals CorporationSeoul National University HospitalAfsluttetSund, mandKorea, Republikken